[موسیقی] سلام امیدوارم که خسته نباشید من من از بچگی با خاک سرکار داشتم. اون موقع‌ها که بچه بودم وقتی با خاک بازی می‌کردم بهم می‌گفتن که مراقب باش خاکی نشی. واقعیتش اینه که من سال‌هاست که خاکی شدم.الان به این ظاهر الانم خیلی نگاه نکنیم. من شب و روز با خاک دارم کار می‌کنم. ما یه بنگاه اقتصادی داریم که حوزه فعالیتش خاکه.همونجور که گفتم شب و روز داریم با خاک کار می‌کنیم. امروز می‌خوام از یه نگاه متفاوت به خاک و محیط زیستمون با شما صحبت بکنم. تا حالا به واژه خاک حتماً فکر کردید به معانیی که این واژه داره.خب مفهو ...

Core Insights - Campbell's Company (CPB) has faced significant challenges in 2025, with its stock down 20.4% year to date, underperforming the S&P 500's 1.8% growth and the Zacks Consumer Staples sector's 6.6% return [1][8] - The company's stock closed at $33.32, just above its 52-week low of $32.83, and is trading below both its 50-day and 200-day moving averages, indicating ongoing weakness in momentum and investor sentiment [4][5] Company Performance - CPB's Snacks segment has been particularly weak, with net sales in the division totaling $1,012 million, down 8% year over year, and organic net sales down 5% when excluding the Pop Secret divestiture [9][10] - The decline in the Snacks segment is attributed to a 5% drop in volume/mix, with net price realization remaining flat, and management expects a slower recovery than initially anticipated [10][11] - The company is also facing persistent cost inflation, leading to a decline in adjusted gross profit margin by 110 basis points to 30.1% in the third quarter of fiscal 2025 [11][12] Financial Outlook - Campbell's has reaffirmed its full-year guidance, projecting organic net sales to range from a 2% decline to flat year over year, with adjusted EBIT estimated to grow 3-5% [13] - Adjusted EPS is expected to decline by 4-1%, in the range of $2.95-$3.05, compared to $3.08 reported in fiscal 2024 [13][14] - The overall operating landscape remains tough, with inflation-driven margin erosion and a subdued earnings outlook contributing to the stock's underperformance [14]

Investment Rating - The report downgrades the investment rating for Hua Hong Semiconductor Ltd from Overweight to Equal-weight [1][6][27] Core Insights - The rising depreciation burden and intense pricing competition in the 8-inch wafer market are expected to lead to gross margin erosion in 2025 and 2026, indicating that the stock appears fairly valued [1][6][38] - The company guided for 2Q25 revenue of US$550-570 million, with a gross margin forecast of 7-9%, reflecting a decline due to increased depreciation costs and the ramp-up of the new 12-inch fab [3][13] - The pricing environment for 8-inch wafers remains soft, which is likely to hinder gross margin recovery for Hua Hong [4][38] Summary by Sections Financial Performance - 1Q25 revenue was US$541 million, showing a 0.3% increase quarter-over-quarter but an 18% decrease year-over-year, with a gross margin of 9.2%, down 2.2 percentage points from the previous quarter [2][11] - The company reported a net income of US$4 million in 1Q25, a significant decline compared to the previous year [11] Guidance and Projections - For 2Q25, the company expects revenue to be between US$550-570 million, with a gross margin of 7-9%, indicating a continued decline in profitability [3][13] - The report revises the 2025 EPS estimate down by 14% but raises the 2026 and 2027 EPS forecasts by 5% and 6%, respectively, due to anticipated capacity and shipment growth trends [23][24] Market Dynamics - The report highlights that the 12-inch wafer demand remains strong, which may gradually drive up prices, while the 8-inch wafer market faces pricing pressure due to increased competition [4][38] - The acquisition of HLMC is noted, with plans for integration by 2026, focusing on overlapping mature-node business [5][38] Valuation - The price target for Hua Hong is raised to HK$34.00 from HK$32.00, reflecting changes in the EPS estimates for 2025-2027 [25][27] - The stock is currently trading at 1.2 times the estimated book value per share for 2025, which is considered fair compared to historical averages [27][39]

Core Viewpoint - Amgen is set to report its first-quarter 2025 results on May 1, with expectations of strong sales driven by volume growth in key products, although pricing pressures may impact overall revenue [1][4]. Sales Estimates - The Zacks Consensus Estimate for first-quarter sales is $7.96 billion, with earnings expected at $4.16 per share [1]. - Specific sales estimates for key products include Evenity at $406 million, Repatha at $616 million, Kyprolis at $381 million, and Blincyto at $333 million [2]. Patent Expiration Impact - Patents for Prolia and Xgeva expired in February 2025 in the U.S., leading to anticipated significant sales erosion due to biosimilar competition, with estimates of $990 million for Prolia and $542 million for Xgeva [3]. New Product Contributions - Newer drugs like Tezspire and Tavneos are expected to contribute positively to top-line growth, alongside the successful launch of Imdelltra for advanced small cell lung cancer [4]. Declining Sales of Established Products - Sales of Enbrel and Otezla are projected to decline due to price reductions and historical trends related to benefit plan changes and increased co-pay expenses [5][6]. Biosimilars Performance - Increased competition is expected to negatively impact revenues from oncology biosimilars, while sales of Amjevita/Amgevita are likely to have increased [7]. - Amgen launched biosimilars Wezlana and Pavblu, with investors keenly observing their sales performance [8]. Operating Margin Expectations - Amgen anticipates the lowest operating margin of the year at around 42% for the first quarter, with R&D costs expected to rise while SG&A costs as a percentage of sales are projected to decline [9]. Earnings Surprise History - Amgen has a strong earnings surprise history, beating estimates in the last four quarters with an average surprise of 5.23% [10]. Earnings Prediction Model - The current model does not predict a definitive earnings beat for Amgen, with an Earnings ESP of -0.05% and a Zacks Rank of 3 [12].